Vivek Subbiah, MD

Vivek Subbiah: Tissue-Agnostic Cancer Therapies Promise to Revolutionize Oncology by Targeting Molecular Drivers - OncoDaily Vivek Subbiah: Tissue-Agnostic Cancer Therapies Promise to Revolutionize Oncology by Targeting Molecular Drivers / cancer, cancer treatment, Headlines,

Tissue-Agnostic Cancer Therapies Promise to Revolutionize Oncology by Targeting Molecular Drivers - Vivek Subbiah

@viveksubbiah.bsky.social

oncodaily.com/voices/vivek...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

Vivek Subbiah: Thrilled to Share My Editorial on the ROME Trial - OncoDaily Vivek Subbiah: Thrilled to Share My Editorial on the ROME Trial / Agnese Fabbri, Alberto Zambelli, Andrea Botticelli, Andrea DeCensi, Annamaria Pessino, Bruna

Thrilled to Share My Editorial on the ROME Trial - Vivek Subbiah

@viveksubbiah.bsky.social

oncodaily.com/voices/vivek...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

Vivek Subbiah: ONE of the Most Impactful Meetings in Rare Cancer Research - OncoDaily Vivek Subbiah: ONE of the Most Impactful Meetings in Rare Cancer Research / cancer, OncoDaily, Oncology, Razelle Kurzrock, Target Cancer Foundation, Think

ONE of the Most Impactful Meetings in Rare Cancer Research - Vivek Subbiah

@viveksubbiah.bsky.social

oncodaily.com/voices/vivek...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

Imperative of Comprehensive Molecular Profiling as Standard of Care for Patients With Rare Cancers | JCO Oncology Practice

2. Need structured approaches for how to evaluate even when an ultra-specific histology driven approach isn't feasible, as @viveksubbiah.bsky.social outlines for rare cancers here: ascopubs.org/doi/10.1200/...

Read the Cancer Discovery Piece: Rethinking Cancer Drug Development through Tumor-Agnostic Precision Medicine by @viveksubbiah.bsky.social doi.org/10.1158/2159...

Vivek Subbiah: ESMO 2025 - Catalyzing Novel Collaborations for Global Impact in Oncology - OncoDaily Vivek Subbiah: ESMO 2025 - Catalyzing Novel Collaborations for Global Impact in Oncology / cancer, ESMO, ESMO 2025, OncoDaily, Oncology, Vivek Subbiah

ESMO 2025 - Catalyzing Novel Collaborations for Global Impact in Oncology - Vivek Subbiah

@viveksubbiah.bsky.social @myesmo.bsky.social

oncodaily.com/voices/esmo-...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMO25

Vivek Subbiah: Honored to Present at ESMO Annual Meeting Young Oncologists Clinical Case Discussions - OncoDaily Vivek Subbiah: Honored to Present at ESMO Annual Meeting Young Oncologists Clinical Case Discussions / cancer, ESMO Annual Meeting, ESMO25, Maximilian Kloft,

Honored to Present at ESMO Annual Meeting Young Oncologists Clinical Case Discussions - Vivek Subbiah

@viveksubbiah.bsky.social @myesmo.bsky.social

oncodaily.com/voices/vivek...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

Vivek Subbiah: Precision Oncology and Modernizing Evidence Standards - OncoDaily Vivek Subbiah: Precision Oncology and Modernizing Evidence Standards / cancer, OncoDaily, Oncology, Razelle Kurzrock, Vivek Subbiah

Precision Oncology and Modernizing Evidence Standards - Vivek Subbiah

@viveksubbiah.bsky.social

oncodaily.com/voices/vivek...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

Vivek Subbiah: ESMO Presidential Dinner is Kicking Off in Berlin - OncoDaily Vivek Subbiah: ESMO Presidential Dinner is Kicking Off in Berlin / cancer, ESMO, ESMO 2025, ESMO 2025 Congress, ESMO Presidential Dinner, ESMO2025, ESMO25,

ESMO Presidential Dinner is Kicking Off in Berlin - Vivek Subbiah

@viveksubbiah.bsky.social @myesmo.bsky.social

oncodaily.com/voices/vivek...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMO #ESMO25 #ESMO2025

Vivek Subbiah: Rethinking Cancer Drug Development Through Tumor-Agnostic Precision Medicine - OncoDaily Vivek Subbiah: Rethinking Cancer Drug Development Through Tumor-Agnostic Precision Medicine / cancer, ESMO, ESMO 2025, ESMO 2025 Congress, ESMO2025, ESMO25,

Rethinking Cancer Drug Development Through Tumor-Agnostic Precision Medicine - Vivek Subbiah

@viveksubbiah.bsky.social

oncodaily.com/voices/vivek...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMO #ESMO25 #ESMO2025

Great #ESMO25 talk by @viveksubbiah.bsky.social on targeting molecular drivers of cancer in a tissue-agnostic manner: for more of his thoughts, check out his @aacrjournals.bsky.social Cancer Discovery piece (online as of October 17) here:

Vivek Subbiah: Smarter Trial Designs - How Project Optimus is Changing Early-Phase Cancer Research - OncoDaily Vivek Subbiah: Smarter Trial Designs - How Project Optimus is Changing Early-Phase Cancer Research / American Society of Clinical Oncology, ASCO, cancer,

Smarter Trial Designs: How Project Optimus is Changing Early-Phase Cancer Research - Vivek Subbiah

@viveksubbiah.bsky.social

oncodaily.com/voices/vivek...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

D-7 until #ESMO25! 👋🇩🇪

Excited to be part of first ever tumor-agnostic scientific track with @viveksubbiah.bsky.social @JulianaRBeale #NiamhColeman

Don’t miss these educational sessions! ⬇️ @myesmo.bsky.social

Vivek Subbiah: Impact of FDA Project Optimus Guidance on Early-Phase Trial Design - OncoDaily Vivek Subbiah: Impact of FDA Project Optimus Guidance on Early-Phase Trial Design / cancer, David Spigel, Deepak Bhamidipati, Gerald Falchook, Howard Burris,

Impact of FDA Project Optimus Guidance on Early-Phase Trial Design - Vivek Subbiah

@viveksubbiah.bsky.social @fda.gov

oncodaily.com/voices/vivek...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

Vivek Subbiah: Honored to Join Global Colleagues and Deliver the Message at the UN for The Last Mile Series - OncoDaily Vivek Subbiah: Honored to Join Global Colleagues and Deliver the Message at the UN for The Last Mile Series / cancer, International Cancer Patient Coalition,

Honored to Join Global Colleagues and Deliver the Message at the UN for The Last Mile Series - Vivek Subbiah

@viveksubbiah.bsky.social

oncodaily.com/voices/vivek...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

When AI rejects your grant proposal: algorithms are helping to make funding decisions A Spanish foundation using an artificial-intelligence tool to screen grant applications says it makes the peer-review process more efficient, but other researchers say it’s a breakdown in trust.

⭐️When AI rejects your grant proposal: algorithms are helping to make funding decisions
A foundation using an AI tool to screen grant applications says it makes the peer-review process more efficient, but other researchers say it’s a breakdown in trust
www.nature.com/articles/d41...

Precision Oncology and Modernizing Evidence Standards: A Critical Commentary on the Cochrane Review

Appropriately critical commentary on cochrane reviews as the apply to matched targeted therapy by @viveksubbiah.bsky.social Journal of Clinical Oncology ascopubs.org/doi/full/10....

PFS benefit noted with adagrasib

10 Must-Read Posts in Immuno-Oncology This Week - OncoDaily 10 Must-Read Posts in Immuno-Oncology This Week / Alex Menzies, Alexander Van Akkooi, AndrewFurness, cancer, chemoimmunotherapy, Christian Blank, David

10 Must-Read Posts in Immuno-Oncology This Week

@viveksubbiah.bsky.social @jiajennyliu.bsky.social @gerryhanna.bsky.social @drjnaidoo.bsky.social

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #IO #ImmuneOncology

Vivek Subbiah: Nature Medicine Study on Molecular Profiling in Meningioma - OncoDaily Vivek Subbiah: Nature Medicine Study on Molecular Profiling in Meningioma / Alexander P. Landry, Andrew Ajisebutu, cancer, Chloe Gui, Farshad Nassiri, Gelareh

Nature Medicine Study on Molecular Profiling in Meningioma - @viveksubbiah.bsky.social

oncodaily.com/science/vive...

#OncoDaily #Oncology #Cancer #Health #Medicine

Vivek Subbiah: Rare Cancers Deserve Breakthroughs Too - OncoDaily Vivek Subbiah: Rare Cancers Deserve Breakthroughs Too / American Society of Clinical Oncology, ASCO, cancer, Conquer Cancer, Conquer Cancer the ASCO

Rare Cancers Deserve Breakthroughs Too - Vivek Subbiah

@viveksubbiah.bsky.social @conquercancer.bsky.social

oncodaily.com/blog/rare-ca...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

Top Articles Suggested by Vivek Subbiah - OncoDaily Top Articles Suggested by Vivek Subbiah / cancer, Nature, NEJM, OncoDaily, Oncology, Vivek Subbiah

Top Articles Suggested by Vivek Subbiah

@viveksubbiah.bsky.social

oncodaily.com/voices/vivek...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

Oral Bacterial and Fungal Microbiome and Subsequent Risk for Pancreatic Cancer Interview with Jiyoung Ahn, PhD, author of Oral Bacterial and Fungal Microbiome and Subsequent Risk for Pancreatic Cancer. Hosted by Vivek Subbiah, MD.

🔊 Listen to Jiyoung Ahn, PhD, of New York University, discuss with @viveksubbiah.bsky.social, MD, about whether the oral bacterial and fungal microbiome is associated with the development of pancreatic #cancer.

Listen now: ja.ma/41Vzuh9

Vivek Subbiah: Congratulations to Petros Grivas on Being Named Medical Director of Fred Hutch Cancer Center - OncoDaily Vivek Subbiah: Congratulations to Petros Grivas on Being Named Medical Director of Fred Hutch Cancer Center / cancer, Fred Hutch Cancer Center, OncoDaily,

Congratulations to Petros Grivas on Being Named Medical Director of Fred Hutch Cancer Center - Vivek Subbiah

@viveksubbiah.bsky.social @fredhutch.org

oncodaily.com/career/vivek...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

Top 5 Articles of the Week Suggested by Vivek Subbiah - OncoDaily Top 5 Articles of the Week Suggested by Vivek Subbiah / cancer, Cancer Discovery, Nature, OncoDaily, Oncology, Sarah Cannon Research Institute, Vivek Subbiah

Top 5 Articles of the Week Suggested by Vivek Subbiah

@viveksubbiah.bsky.social

oncodaily.com/voices/vivek...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial Adagrasib demonstrated a statistically significant improvement in progression-free survival over docetaxel in patients with previously treated KRASG12C-mutated NSCLC, without new safety signals.

Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial - The Lancet www.thelancet.com/journals/lan...

Patterns in genomic mutations among patients with early-onset colorectal cancer: an international, multicohort, observational study Within hypermutated colorectal cancer, younger patients exhibited a higher mutational burden than older patients. Our study reveals an abnormal accumulation of distinct somatic mutations in hypermutat...

Patterns in genomic mutations among patients with early-onset colorectal cancer: an international, multicohort, observational study - The Lancet Oncology www.thelancet.com/journals/lan...

Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol We did not find significant evidence of an overall survival benefit of adding metformin to standard of care in the overall population of patients with metastatic hormone-sensitive prostate cancer. The...

Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol - The Lancet Oncology www.thelancet.com/journals/lan...

Vivek Subbiah: We Don’t Just Write What We Know, We Write to Discover What We Could Know - OncoDaily Vivek Subbiah: We Don’t Just Write What We Know, We Write to Discover What We Could Know / cancer, Nature Reviews Bioengineering, OncoDaily, Oncology, Vivek

What is Missing to Fully Harness Precision Medicine and Transform Cancer Care - Vivek Subbiah
@viveksubbiah.bsky.social
@natmed.nature.com

oncodaily.com/blog/vivek-s...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #PrecisionMedicine

Vivek Subbiah: It’s Time We Evolve WHO Cancer Classification - OncoDaily Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn: “Happy 4th everyone! Delighted to share with the our comment just published in t...

It’s Time We Evolve WHO Cancer Classification - Vivek Subbiah
@viveksubbiah.bsky.social
@who.int

oncodaily.com/science/vive...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #CancerClassification #WHO